Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Roche Seeks to Extend Antitrust Waiting Period for Illumina Bid

This article has been updated from a previous version to clarify that Roche is seeking to extend the antitrust waiting period for its bid, not the timeline for the tender offer.

NEW YORK (GenomeWeb News) – Roche is seeking to extend the antitrust waiting period required for its $5.7 billion hostile bid for Illumina, it said in a document filed with the US Securities and Exchange Commission.

In the filing, Roche said it will file necessary paperwork on Feb. 27 to extend the required waiting period under the Hart-Scott-Rodino at to expire at the end of the day March 13. The US Antitrust Division or Federal Trade Commission may further extend the waiting period, Roche noted in the filing.

Roche is offering $44.50 per share of Illumina's stock. Illumina has rejected the bid and implemented a poison pill plan. Roche named its nominees for Illumina's board a few weeks ago as part of its hostile bid.

Shareholders have filed a lawsuit against Illumina alleging conflict of interest and breach of fiduciary responsibilities.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.